Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26146924 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Zoran Gavrilov und 1 weiteren Autor:innen. Beteiligte Einrichtung: Lab for Retinal Gene Therapy, Department Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, 8952 Schlieren, Switzerland. Hauptthemen laut MEDLINE: Sarcopenia, Osteoporosis, Bone Density Conservation Agents. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 281 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Slovenian Research and Innovation Agency, University Medical Centre Ljubljana, Slovenian research and innovation agency ARIS.
Abstract (Originalsprache)
Osteoporosis and sarcopenia are two aspects of the geriatric syndrome that frequently occur together and affect one another in a condition referred to as osteosarcopenia. Preventive and treatment options for osteosarcopenia exist but are mainly focused on the treatment of osteoporosis, as there is still no FDA-approved treatment for sarcopenia. Drugs for osteoporosis include antiresorptive and anabolic drugs and hormonal replacement therapies and are prescribed based on age, BMD and other patient characteristics, which, however, do not include the possible co-existence of sarcopenia. As several studies and clinical trials have shown that the pharmacological treatment of osteoporosis can also affect muscle tissue, in either a positive or negative manner, sarcopenia should be another factor affecting the choice of treatment, especially when facing equal treatment options for osteoporosis. The aim of this review was to summarize our current knowledge on the effects of FDA-approved drugs for the treatment of osteoporosis on muscle quality, mass and function. A better understanding of the effects that certain drugs have on muscle tissue might in the future help us to simultaneously at least partially also address the wasting of muscle tissue and avoid further pharmacologically induced decline.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Lab for Retinal Gene Therapy, Department Ophthalmology, University Hospital Zurich, University of Zurich, Wagistrasse 14, 8952 Schlieren, Switzerland.
- Department of Clinical Biochemistry, Faculty of Pharmacy, University of Ljubljana, Aškerčeva cesta 7, 1000 Ljubljana, Slovenia.
- Clinical Institute for Clinical Chemistry and Biochemistry, University Medical Centre Ljubljana, Njegoševa cesta 4, 1000 Ljubljana, Slovenia.
Förderung
- The Slovenian Research and Innovation Agency
- University Medical Centre Ljubljana
- Slovenian research and innovation agency ARIS
Zitieren
APA
Gavrilov, Z., & Lojk, J. (2025). Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26146924
Vancouver
Gavrilov Z, Lojk J. Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26146924
BibTeX
@article{Gavrilov2025,
author = {Gavrilov, Zoran and Lojk, Jasna},
title = {Rethinking Osteoporosis Drugs: Can We Simultaneously Address Sarcopenia?},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26146924}
}
EUVIMED